Celcuity LLC (CELC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.15B
Last updated: Nov 17, 2026 at 11:05 AM ET
Celcuity LLC (CELC) Stock Forecast
Analysts expect Celcuity LLC (CELC) to earn -$4.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $14.26M. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 23.1% |
| Buy | 10 | 76.9% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 1890.0%.
- Fiscal year ending Dec 31, 2026
- -$4.28
- EPS consensus, revenue $14.26M
- Fiscal year ending Dec 31, 2027
- -$0.01
- EPS consensus, revenue $283.77M
- Next report
- Mar 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.28 | -$4.32 to -$4.23 | 2 | $14.26M | $6.50M to $20.00M | 10 |
| Dec 31, 2027 | -$0.01 | -$1.21 to $1.20 | 2 | $283.77M | $120.00M to $488.06M | 11 |
Quarterly Estimates
The EPS consensus rises from -$1.41 for the quarter ending Dec 31, 2026 to -$1.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.41 | -$1.86 to -$1.12 | 14 | $13.87M | $6.37M to $21.00M | 13 |
| Mar 31, 2027 | -$1.08 | -$1.08 to -$1.08 | 1 | $31.89M | $17.60M to $40.00M | 6 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.77.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.28 | -$4.39 | -$4.39 | -$4.39 | -$3.77 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.01 | -$0.08 | -$0.08 | -$0.08 | $0.96 | N/A |
| Quarter ending Mar 31, 2027 | -$1.08 | -$0.93 | -$0.93 | -$0.93 | -$0.89 | N/A |
Frequently Asked Questions About CELC
What is the CELC stock forecast?
Consensus analyst estimates put Celcuity LLC's EPS at -$4.28 for the fiscal year ending Dec 31, 2026, on revenue of $14.26M. The consensus rating from 13 analysts is Buy.
How do analysts rate CELC stock?
Of 13 analysts covering Celcuity LLC, 3 rate it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CELC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.28, with estimates from -$4.32 to -$4.23 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.01, with estimates from -$1.21 to $1.20 from 2 analysts.
What revenue do analysts expect from Celcuity LLC next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $14.26M, with estimates from $6.50M to $20.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $283.77M, with estimates from $120.00M to $488.06M.
How many analysts cover CELC?
13 analysts rate Celcuity LLC stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CELC pages: Overview, Earnings, Forecast, Financials, Competitors